The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape is undergoing a significant transformation, marked by the continued brand dominance of Merck’s Keytruda (pembrolizumab)…
Read More
Pharma 50: Keytruda Holds Top Brand Slot as Tirzepatide and Semaglutide Dominate at Molecule Level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant transformation in fiscal year 2025, revealing a nuanced shift in leadership despite…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
